Table of Contents Author Guidelines Submit a Manuscript
Table of Contents Alerts

To receive news and publication updates for The Scientific World Journal, enter your email address in the box below.

The Scientific World Journal
Volume 2015 (2015), Article ID 716514, 19 pages
http://dx.doi.org/10.1155/2015/716514
Review Article

Development of PET and SPECT Probes for Glutamate Receptors

Takeshi Fuchigami, Morio Nakayama, and Sakura Yoshida

Department of Hygienic Chemistry, Graduate School of Biomedical Sciences, Nagasaki University, 1-14 Bunkyo-machi, Nagasaki 852-8521, Japan

Received 28 June 2014; Accepted 29 August 2014

Academic Editor: Masahiro Ono

Copyright © 2015 Takeshi Fuchigami et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. F. Traynelis, L. P. Wollmuth, C. J. McBain et al., “Glutamate receptor ion channels: Structure, regulation, and function,” Pharmacological Reviews, vol. 62, no. 3, pp. 405–496, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. C. M. Niswender and P. J. Conn, “Metabotropic glutamate receptors: physiology, pharmacology, and disease,” Annual Review of Pharmacology and Toxicology, vol. 50, pp. 295–322, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. D. Bowie, “Ionotropic glutamate receptors & CNS disorders,” CNS and Neurological Disorders—Drug Targets, vol. 7, no. 2, pp. 129–143, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Lau and M. Tymianski, “Glutamate receptors, neurotoxicity and neurodegeneration,” Pflugers Archiv European Journal of Physiology, vol. 460, no. 2, pp. 525–542, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Riedel, B. Platt, and J. Micheau, “Glutamate receptor function in learning and memory,” Behavioural Brain Research, vol. 140, no. 1-2, pp. 1–47, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. C. G. Lau and R. S. Zukin, “NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders,” Nature Reviews Neuroscience, vol. 8, no. 6, pp. 413–426, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. J. A. Kemp and R. M. McKernan, “NMDA receptor pathways as drug targets,” Nature Neuroscience, vol. 5, pp. 1039–1042, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. L. V. Kalia, S. K. Kalia, and M. W. Salter, “NMDA receptors in clinical neurology: excitatory times ahead,” The Lancet Neurology, vol. 7, no. 8, pp. 742–755, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Dingledine, K. Borges, D. Bowie, and S. F. Traynelis, “The glutamate receptor ion channels,” Pharmacological Reviews, vol. 51, no. 1, pp. 7–61, 1999. View at Google Scholar · View at Scopus
  10. B. Laube, J. Kuhse, and H. Betz, “Evidence for a tetrameric structure of recombinant NMDA receptors,” Journal of Neuroscience, vol. 18, no. 8, pp. 2954–2961, 1998. View at Google Scholar · View at Scopus
  11. H. Furukawa, S. K. Singh, R. Mancusso, and E. Gouaux, “Subunit arrangement and function in NMDA receptors,” Nature, vol. 438, no. 7065, pp. 185–192, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. M. H. Ulbrich and E. Y. Isacoff, “Rules of engagement for NMDA receptor subunits,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 37, pp. 14163–14168, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. P. Paoletti and J. Neyton, “NMDA receptor subunits: function and pharmacology,” Current Opinion in Pharmacology, vol. 7, no. 1, pp. 39–47, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. C.-M. Low and K. S.-L. Wee, “New insights into the not-so-new NR3 subunits of N-methyl-D-aspartate receptor: localization, structure, and function,” Molecular Pharmacology, vol. 78, no. 1, pp. 1–11, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. H. Furukawa and E. Gouaux, “Mechanisms of activation, inhibition and specificity: crystal structures of the NMDA receptor NR1 ligand-binding core,” EMBO Journal, vol. 22, no. 12, pp. 2873–2885, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Yao, C. B. Harrison, P. L. Freddolino, K. Schulten, and M. L. Mayer, “Molecular mechanism of ligand recognition by NR3 subtype glutamate receptors,” The EMBO Journal, vol. 27, no. 15, pp. 2158–2170, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Mony, J. N. C. Kew, M. J. Gunthorpe, and P. Paoletti, “Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential,” British Journal of Pharmacology, vol. 157, no. 8, pp. 1301–1317, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. N. A. Anis, S. C. Berry, N. R. Burton, and D. Lodge, “The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate,” British Journal of Pharmacology, vol. 79, no. 2, pp. 565–575, 1983. View at Publisher · View at Google Scholar · View at Scopus
  19. A. C. Foster and E. H. F. Wong, “The novel anticonvulsant MK-801 binds to the activated state of the N-methyl-D-aspartate receptor in rat brain,” British Journal of Pharmacology, vol. 91, no. 2, pp. 403–409, 1987. View at Publisher · View at Google Scholar · View at Scopus
  20. E. Karakas, N. Simorowski, and H. Furukawa, “Subunit arrangement and phenylethanolamine binding in GluN1/GluN2B NMDA receptors,” Nature, vol. 475, no. 7355, pp. 249–253, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. J. N. C. Kew and J. A. Kemp, “Ionotropic and metabotropic glutamate receptor structure and pharmacology,” Psychopharmacology, vol. 179, no. 1, pp. 4–29, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Loo, A. Braunwalder, J. Lehmann, and M. Williams, “Radioligand binding to central phencyclidine recognition sites is dependent on excitatory amino acid receptor agonists,” European Journal of Pharmacology, vol. 123, no. 3, pp. 467–468, 1986. View at Publisher · View at Google Scholar · View at Scopus
  23. E. H. F. Wong, A. R. Knight, and G. N. Woodruff, “[3H]MK-801 labels a site on the N-methyl-D-aspartate receptor channel complex in rat brain membranes,” Journal of Neurochemistry, vol. 50, no. 1, pp. 274–281, 1988. View at Publisher · View at Google Scholar · View at Scopus
  24. K. Orita, S. Sasaki, M. Maeda et al., “Synthesis and evaluation of 1-{1-[5-(2′-[18F]Fluoroethyl)-2-thienyl]-cyclohexyl}piperidine as a potential in vivo radioligand for the NMDA receptor-Channel complex,” Nuclear Medicine and Biology, vol. 20, no. 7, pp. 865–873, 1993. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Sihver, W. Sihver, Y. Andersson et al., “In vitro and in vivo characterization of (+)-3-[11C]cyano-dizocilpine,” Journal of Neural Transmission, vol. 105, no. 2-3, pp. 117–131, 1998. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Owens, A. A. Tebbutt, A. L. McGregor et al., “Synthesis and binding characteristics of N-(1-naphthyl)-N′-(3-[125I]-iodophenyl)-N′-methylguanidine ([125I]-CNS 1261): a potential SPECT agent for imaging NMDA receptor activation,” Nuclear Medicine and Biology, vol. 27, no. 6, pp. 557–564, 2000. View at Publisher · View at Google Scholar · View at Scopus
  27. K. Erlandsson, R. A. Bressan, R. S. Mulligan et al., “Kinetic modelling of [123I]CNS 1261—a potential SPET tracer for the NMDA receptor,” Nuclear Medicine and Biology, vol. 30, no. 4, pp. 441–454, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. R. A. Bressan, K. Erlandsson, R. S. Mulligan et al., “A bolus/infusion paradigm for the novel NMDA receptor SPET tracer [123I]CNS 1261,” Nuclear Medicine and Biology, vol. 31, no. 2, pp. 155–164, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. J. T. Kantrowitz and D. C. Javitt, “N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?” Brain Research Bulletin, vol. 83, no. 3-4, pp. 108–121, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. C. H. Lin, H. Y. Lane, and G. E. Tsai, “Glutamate signaling in the pathophysiology and therapy of schizophrenia,” Pharmacology Biochemistry and Behavior, vol. 100, no. 4, pp. 665–677, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. L. S. Pilowsky, R. A. Bressan, J. M. Stone et al., “First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients,” Molecular Psychiatry, vol. 11, no. 2, pp. 118–119, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. R. A. Bressan, K. Erlandsson, J. M. Stone et al., “Impact of schizophrenia and chronic antipsychotic treatment on [123I]CNS-1261 binding to N-methyl-D-aspartate receptors in vivo,” Biological Psychiatry, vol. 58, no. 1, pp. 41–46, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. R. N. Waterhouse, M. Slifstein, F. Dumont et al., “In vivo evaluation of [11C]N-(2-chloro-5-thiomethylphenyl)- N′-(3-methoxy-phenyl)-N′-methylguanidine ([11C]GMOM) as a potential PET radiotracer for the PCP/NMDA receptor,” Nuclear Medicine and Biology, vol. 31, no. 7, pp. 939–948, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Biegon, A. Gibbs, M. Alvarado, M. Ono, and S. Taylor, “In vitro and in vivo characterization of [3H]CNS-5161—a use-dependent ligand for the N-methyl-D-aspartate receptor in rat brain,” Synapse, vol. 61, no. 8, pp. 577–586, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. M. C. Asselin, A. Hammers, D. Turton, S. Osman, M. Koepp, and D. Brooks, “Initial kinetic analysis of the in vivo binding of the putative NMDA receptor ligand [11C]CNS 5161 in humans,” Neuroimage, vol. 22, p. T137, 2004. View at Google Scholar
  36. E. G. Robins, Y. Zhao, I. Khan, A. Wilson, S. K. Luthra, and E. Årstad, “Synthesis and in vitro evaluation of 18F-labelled S-fluoroalkyl diarylguanidines: novel high-affinity NMDA receptor antagonists for imaging with PET,” Bioorganic and Medicinal Chemistry Letters, vol. 20, no. 5, pp. 1749–1751, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. C. J. McGinnity, A. Hammers, D. A. R. Barros et al., “Initial evaluation of 18F-GE-179, a putative PEt tracer for activated N-methyl D-aspartate receptors,” Journal of Nuclear Medicine, vol. 55, no. 3, pp. 423–430, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. W. Danysz and C. G. Parsons, “Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications,” Pharmacological Reviews, vol. 50, no. 4, pp. 597–664, 1998. View at Google Scholar · View at Scopus
  39. R. N. Waterhouse, A. Sultana, and M. Laruelle, “In vivo evaluation of [11C]-3-[2-[(3-methoxyphenylamino)carbonyl]ethenyl]-4,6- dichloroindole-2-carboxylic acid ([11C]3MPICA) as a PET radiotracer for the glycine site of the NMDA ion channel,” Nuclear Medicine and Biology, vol. 29, no. 8, pp. 791–794, 2002. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Piel, R. Schirrmacher, S. Höhnemann et al., “Synthesis and evaluation of 5, 7-dichloro-4-(3-{ 4-[4-(2-[18F]fluoroethyl)-piperazin-1-yl]-phenyl}-ureido)-1, 2, 3, 4-tetrahydroquinoline-2-carboxylic acid as a potential NMDA ligand to study glutamatergic neurotransmission in vivo,” Journal of Labelled Compounds and Radiopharmaceuticals, vol. 46, pp. 645–659, 2003. View at Google Scholar
  41. J. J. Kulagowski, R. Baker, N. R. Curtis et al., “3′-(Arylmethyl)- and 3′-(aryloxy)-3-phenyl-4-hydroxyquinolin-2(1H)-ones: orally active antagonists of the glycine site on the NMDA receptor,” Journal of Medicinal Chemistry, vol. 37, no. 10, pp. 1402–1405, 1994. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Rowley, J. J. Kulagowski, A. P. Watt et al., “Effect of plasma protein binding-on in vivo activity and brain penetration of glycine/NMDA receptor antagonists,” Journal of Medicinal Chemistry, vol. 40, no. 25, pp. 4053–4068, 1997. View at Publisher · View at Google Scholar · View at Scopus
  43. T. Haradahira, M.-R. Zhang, J. Maeda et al., “A strategy for increasing the brain uptake of a radioligand in animals: use of a drug that inhibits plasma protein binding,” Nuclear Medicine and Biology, vol. 27, no. 4, pp. 357–360, 2000. View at Publisher · View at Google Scholar · View at Scopus
  44. T. Haradahira, M.-R. Zhang, J. Maeda et al., “A prodrug of NMDA/Glycine site antagonist, L-703,717, with improved BBB permeability: 4-acetoxy derivative and its positron-emitter labeled analog,” Chemical and Pharmaceutical Bulletin, vol. 49, no. 2, pp. 147–150, 2001. View at Publisher · View at Google Scholar · View at Scopus
  45. R. Matsumoto, T. Haradahira, H. Ito et al., “Measurement of glycine binding site of N-methyl-D-asparate receptors in living human brain using 4-acetoxy derivative of L-703,717, 4-acetoxy-7-chloro- 3-[3-(4-[11C] methoxybenzyl) phenyl]-2(1H)-quinolone (AcL703) with positron emission tomography,” Synapse, vol. 61, no. 10, pp. 795–800, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. T. Fuchigami, T. Haradahira, N. Fujimoto et al., “Difference in brain distributions of carbon 11-labeled 4-hydroxy-2(1H)-quinolones as PET radioligands for the glycine-binding site of the NMDA ion channel,” Nuclear Medicine and Biology, vol. 35, no. 2, pp. 203–212, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. T. Fuchigami, T. Haradahira, N. Fujimoto et al., “Development of N-[11C]methylamino 4-hydroxy-2(1H)-quinolone derivatives as PET radioligands for the glycine-binding site of NMDA receptors,” Bioorganic and Medicinal Chemistry, vol. 17, no. 15, pp. 5665–5675, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Hashimoto, T. Nishikawa, T. Oka, and K. Takahashi, “Endogenous D-serine in rat brain: N-methyl-D-aspartate receptor-related distribution and aging,” Journal of Neurochemistry, vol. 60, no. 2, pp. 783–786, 1993. View at Publisher · View at Google Scholar · View at Scopus
  49. M. J. Schell, R. O. Brady Jr., M. E. Molliver, and S. H. Snyder, “D-serine as a neuromodulator: regional and developmental localizations in rat brain glia resemble NMDA receptors,” Journal of Neuroscience, vol. 17, no. 5, pp. 1604–1615, 1997. View at Google Scholar · View at Scopus
  50. M. J. Schell, M. E. Molliver, and S. H. Snyder, “D-serine, an endogenous synaptic modulator: localization to astrocytes and glutamate-stimulated release,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 9, pp. 3948–3952, 1995. View at Publisher · View at Google Scholar · View at Scopus
  51. T. Haradahira, T. Okauchi, J. Maeda et al., “Effects of endogenous agonists, glycine and D-serine, on in vivo specific binding of [11C]L-703,717, a PET radioligand for the glycine-binding site of NMDA receptors,” Synapse, vol. 50, no. 2, pp. 130–136, 2003. View at Publisher · View at Google Scholar · View at Scopus
  52. K. R. Gogas, “Glutamate-based therapeutic approaches: NR2B receptor antagonists,” Current Opinion in Pharmacology, vol. 6, no. 1, pp. 68–74, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. P. Malherbe, V. Mutel, C. Broger et al., “Identification of critical residues in the amino terminal domain of the human NR2B subunit involved in the RO 25-6981 binding pocket,” Journal of Pharmacology and Experimental Therapeutics, vol. 307, no. 3, pp. 897–905, 2003. View at Publisher · View at Google Scholar · View at Scopus
  54. F. Menniti, B. Chenard, M. Collins, M. Ducat, I. Shalaby, and F. White, “CP-101,606, a potent neuroprotectant selective for forebrain neurons,” European Journal of Pharmacology, vol. 331, no. 2-3, pp. 117–126, 1997. View at Publisher · View at Google Scholar · View at Scopus
  55. T. Haradahira, J. Maeda, T. Okauchi et al., “Synthesis, in vitro and in vivo pharmacology of a C-11 labeled analog of CP-101,606, (±)threo-1-(4-hydroxyphenyl)-2-[4-hydroxy-4- (p-[11C]methoxyphenyl)piperidino]-1-propanol, as a PET tracer for NR2B subunit-containing NMDA receptors,” Nuclear Medicine and Biology, vol. 29, no. 5, pp. 517–525, 2002. View at Publisher · View at Google Scholar · View at Scopus
  56. H. Mori and M. Mishina, “Structure and function of the NMDA receptor channel,” Neuropharmacology, vol. 34, no. 10, pp. 1219–1237, 1995. View at Publisher · View at Google Scholar · View at Scopus
  57. G. Roger, B. Lagnel, L. Besret et al., “Synthesis, radiosynthesis and in vivo evaluation of 5-[3-(4- benzylpiperidin-1-yl)prop-1-ynyl]-1,3-dihydrobenzoimidazol-2-[ 11C]one, as a potent NR1A/2B subtype selective NMDA PET radiotracer,” Bioorganic and Medicinal Chemistry, vol. 11, no. 24, pp. 5401–5408, 2003. View at Publisher · View at Google Scholar · View at Scopus
  58. G. Roger, F. Dollé, B. de Bruin et al., “Radiosynthesis and pharmacological evaluation of [11C]EMD-95885: a high affinity ligand for NR2B-containing NMDA receptors,” Bioorganic and Medicinal Chemistry, vol. 12, no. 12, pp. 3229–3237, 2004. View at Publisher · View at Google Scholar · View at Scopus
  59. T. Fuchigami, H. Yamaguchi, M. Ogawa et al., “Synthesis and biological evaluation of radio-iodinated benzimidazoles as SPECT imaging agents for NR2B subtype of NMDA receptor,” Bioorganic and Medicinal Chemistry, vol. 18, no. 21, pp. 7497–7506, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. F. Dollé, H. Valette, S. Demphel et al., “Radiosynthesis and in vivo evaluation of [11C]Ro-647312: A novel NR1/2B subtype selective NMDA receptor radioligand,” Journal of Labelled Compounds and Radiopharmaceuticals, vol. 47, no. 13, pp. 911–920, 2004. View at Publisher · View at Google Scholar · View at Scopus
  61. E. Årstad, S. Platzer, A. Berthele et al., “Towards NR2B receptor selective imaging agents for PET-synthesis and evaluation of N-[11C]-(2-methoxy)benzyl (E)-styrene-, 2-naphthyl- and 4-trifluoromethoxyphenylamidine,” Bioorganic and Medicinal Chemistry, vol. 14, no. 18, pp. 6307–6313, 2006. View at Publisher · View at Google Scholar · View at Scopus
  62. C. Addy, C. Assaid, D. Hreniuk et al., “Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease,” Journal of Clinical Pharmacology, vol. 49, no. 7, pp. 856–864, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. R. Koudih, G. Gilbert, M. Dhilly et al., “Synthesis and in vitro characterization of trans- and cis-[18F]-4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]-3- fluoropiperidine-1-carboxylates as new potential PET radiotracer candidates for the NR2B subtype N-methyl-d-aspartate receptor,” European Journal of Medicinal Chemistry, vol. 53, pp. 408–415, 2012. View at Publisher · View at Google Scholar · View at Scopus
  64. N. Pitsikas, “The metabotropic glutamate receptors: potential drug targets for the treatment of anxiety disorders?” European Journal of Pharmacology, vol. 723, no. 1, pp. 181–184, 2014. View at Publisher · View at Google Scholar · View at Scopus
  65. S. Chaki, Y. Ago, A. Palucha-Paniewiera, F. Matrisciano, and A. Pilc, “MGlu2/3 and mGlu5 receptors: potential targets for novel antidepressants,” Neuropharmacology, vol. 66, pp. 40–52, 2013. View at Publisher · View at Google Scholar · View at Scopus
  66. H.-G. Lee, X. Zhu, M. J. O'Neill et al., “The role of metabotropic glutamate receptors in Alzheimer's disease,” Acta Neurobiologiae Experimentalis, vol. 64, no. 1, pp. 89–98, 2004. View at Google Scholar · View at Scopus
  67. P. N. Vinson and P. J. Conn, “Metabotropic glutamate receptors as therapeutic targets for schizophrenia,” Neuropharmacology, vol. 62, no. 3, pp. 1461–1472, 2012. View at Publisher · View at Google Scholar · View at Scopus
  68. F. Gasparini, T. Di Paolo, and B. Gomez-Mancilla, “Metabotropic glutamate receptors for parkinson's disease therapy,” Parkinson's Disease, vol. 2013, Article ID 196028, 11 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  69. R. T. Ngomba, I. Santolini, T. E. Salt et al., “Metabotropic glutamate receptors in the thalamocortical network: Strategic targets for the treatment of absence epilepsy,” Epilepsia, vol. 52, no. 7, pp. 1211–1222, 2011. View at Publisher · View at Google Scholar · View at Scopus
  70. F. Nicoletti, J. Bockaert, G. L. Collingridge et al., “Metabotropic glutamate receptors: from the workbench to the bedside,” Neuropharmacology, vol. 60, no. 7-8, pp. 1017–1041, 2011. View at Publisher · View at Google Scholar · View at Scopus
  71. F. Ferraguti and R. Shigemoto, “Metabotropic glutamate receptors,” Cell and Tissue Research, vol. 326, no. 2, pp. 483–504, 2006. View at Publisher · View at Google Scholar · View at Scopus
  72. A. Slassi, M. Isaac, L. Edwards et al., “Recent advances in non-competitive mGlu5 receptor antogonists and their potential therapeutic applications,” Current Topics in Medicinal Chemistry, vol. 5, no. 9, pp. 897–911, 2005. View at Publisher · View at Google Scholar · View at Scopus
  73. P. J. Conn, C. W. Lindsley, and C. K. Jones, “Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia,” Trends in Pharmacological Sciences, vol. 30, no. 1, pp. 25–31, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. Y. Huang, R. Narendran, F. Bischoff et al., “A positron emission tomography radioligand for the in vivo labeling of metabotropic glutamate 1 receptor: (3-Ethyl-2-[11C]methyl-6- quinolinyl)(cis-4-methoxycyclohexyl)methanone,” Journal of Medicinal Chemistry, vol. 48, no. 16, pp. 5096–5099, 2005. View at Publisher · View at Google Scholar · View at Scopus
  75. Y. Huang, R. Narendran, F. Bischoff et al., “Synthesis and characterization of two pet radioligands for the metabotropic glutamate 1 (mGlu1) receptor,” Synapse, vol. 66, no. 12, pp. 1002–1014, 2012. View at Publisher · View at Google Scholar · View at Scopus
  76. K. Yanamoto, F. Konno, C. Odawara et al., “Radiosynthesis and evaluation of [11C]YM-202074 as a PET ligand for imaging the metabotropic glutamate receptor type 1,” Nuclear Medicine and Biology, vol. 37, no. 5, pp. 615–624, 2010. View at Publisher · View at Google Scholar · View at Scopus
  77. E. D. Hostetler, W. Eng, A. D. Joshi et al., “Synthesis, characterization, and monkey PET studies of [18F]MK-1312, a PET tracer for quantification of mGluR1 receptor occupancy by MK-5435,” Synapse, vol. 65, no. 2, pp. 125–135, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. M. Fujinaga, J. Maeda, J. Yui et al., “Characterization of 1-(2-[18F]fluoro-3-pyridyl)-4-(2-isopropyl- 1-oxo- isoindoline-5-yl)-5-methyl-1H-1,2,3-triazole, a PET ligand for imaging the metabotropic glutamate receptor type 1 in rat and monkey brains,” Journal of Neurochemistry, vol. 121, no. 1, pp. 115–124, 2012. View at Publisher · View at Google Scholar · View at Scopus
  79. A. Satoh, Y. Nagatomi, Y. Hirata et al., “Discovery and in vitro and in vivo profiles of 4-fluoro-N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-methylbenzamide as novel class of an orally active metabotropic glutamate receptor 1 (mGluR1) antagonist,” Bioorganic and Medicinal Chemistry Letters, vol. 19, no. 18, pp. 5464–5468, 2009. View at Publisher · View at Google Scholar · View at Scopus
  80. T. Yamasaki, M. Fujinaga, Y. Yoshida et al., “Radiosynthesis and preliminary evaluation of 4-[18F]fluoro-N-[4- [6-(isopropylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-methylbenzamide as a new positron emission tomography ligand for metabotropic glutamate receptor subtype 1,” Bioorganic and Medicinal Chemistry Letters, vol. 21, no. 10, pp. 2998–3001, 2011. View at Publisher · View at Google Scholar · View at Scopus
  81. T. Yamasaki, M. Fujinaga, J. Maeda et al., “Imaging for metabotropic glutamate receptor subtype 1 in rat and monkey brains using PET with [18F]FITM,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 39, no. 4, pp. 632–641, 2012. View at Publisher · View at Google Scholar · View at Scopus
  82. T. Yamasaki, M. Fujinaga, K. Kawamura et al., “In vivo measurement of the affinity and density of metabotropic glutamate receptor subtype 1 in rat brain using 18F-FITM in small-animal PET,” Journal of Nuclear Medicine, vol. 53, no. 10, pp. 1601–1607, 2012. View at Publisher · View at Google Scholar · View at Scopus
  83. M. Fujinaga, T. Yamasaki, J. Yui et al., “Synthesis and evaluation of novel radioligands for positron emission tomography imaging of metabotropic glutamate receptor subtype 1 (mGluR1) in rodent brain,” Journal of Medicinal Chemistry, vol. 55, no. 5, pp. 2342–2352, 2012. View at Publisher · View at Google Scholar · View at Scopus
  84. J. Yui, L. Xie, M. Fujinaga et al., “Monitoring neuroprotective effects using positron emission tomography with [11C]ITMM, a radiotracer for metabotropic glutamate 1 receptor,” Stroke, vol. 44, no. 9, pp. 2567–2572, 2013. View at Publisher · View at Google Scholar · View at Scopus
  85. J. Toyohara, M. Sakata, K. Oda et al., “Initial human PET studies of metabotropic glutamate receptor type 1 ligand 11C-ITMM,” Journal of Nuclear Medicine, vol. 54, no. 8, pp. 1302–1307, 2013. View at Publisher · View at Google Scholar · View at Scopus
  86. M. Fujinaga, T. Yamasaki, J. Maeda et al., “Development of N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-methyl-4-[11C]methylbenzamide for positron emission tomography imaging of metabotropic glutamate 1 receptor in monkey brain,” Journal of Medicinal Chemistry, vol. 55, no. 24, pp. 11042–11051, 2012. View at Publisher · View at Google Scholar · View at Scopus
  87. T. Yamasaki, J. Maeda, M. Fujinaga et al., “PET brain kinetics studies of 11C-ITMM and 11C-ITDM, radioprobes for metabotropic glutamate receptor type 1, in a nonhuman primate,” The American Journal of Nuclear Medicine and Molecular Imaging, vol. 4, pp. 260–269, 2014. View at Google Scholar
  88. T. Yamasaki, M. Fujinaga, J. Yui et al., “Noninvasive quantification of metabotropic glutamate receptor type 1 with [11C]ITDM: a small-animal PET study,” Journal of Cerebral Blood Flow and Metabolism, vol. 34, no. 4, pp. 606–612, 2014. View at Publisher · View at Google Scholar · View at Scopus
  89. R. Xu, P. Zanotti-Fregonara, S. S. Zoghbi et al., “Synthesis and evaluation in monkey of [18F]4-Fluoro- N-methyl-N-(4-(6-(methylamino)pyrimidin-4-yl)thiazol-2-yl)benzamide ([ 18F]FIMX): a promising radioligand for PET imaging of brain metabotropic glutamate receptor 1 (mGluR1),” Journal of Medicinal Chemistry, vol. 56, no. 22, pp. 9146–9155, 2013. View at Publisher · View at Google Scholar · View at Scopus
  90. P. Zanotti-Fregonara, S. Zoghbi, J. S. Liow et al., “[18F]FIMX is a promising tracer to quantify metabotropic glutamate receptor 1 (mGluR1) in human brain,” Journal of Nuclear Medicine, vol. 55, supplement 1, p. 359, 2014. View at Google Scholar
  91. T. G. Hamill, S. Krause, C. Ryan et al., “Synthesis, characterization, and first successful monkey imaging studies of metabotropic glutamate receptor subtype 5 (mGluR5) PET radiotracers,” Synapse, vol. 56, no. 4, pp. 205–216, 2005. View at Publisher · View at Google Scholar · View at Scopus
  92. J.-Q. Wang, W. Tueckmantel, A. Zhu, D. Pellegrino, and A.-L. Brownell, “Synthesis and preliminary biological evaluation of 3-[18F] fluoro-5-(2-pyridinylethynyl)benzonitrile as a PET radiotracer for imaging metabotropic glutamate receptor subtype 5,” Synapse, vol. 61, no. 12, pp. 951–961, 2007. View at Publisher · View at Google Scholar · View at Scopus
  93. D. F. Wong, R. Waterhouse, H. Kuwabara et al., “18F-FPEB, a PET radiopharmaceutical for quantifying metabotropic glutamate 5 receptors: a first-in-human study of radiochemical safety, biokinetics, and radiation dosimetry,” Journal of Nuclear Medicine, vol. 54, no. 3, pp. 388–396, 2013. View at Publisher · View at Google Scholar · View at Scopus
  94. S. M. Ametamey, L. J. Kessler, M. Honer et al., “Radiosynthesis and preclinical evaluation of 11C-ABP688 as a probe for imaging the metabotropic glutamate receptor subtype 5,” Journal of Nuclear Medicine, vol. 47, no. 4, pp. 698–705, 2006. View at Google Scholar · View at Scopus
  95. S. M. Ametamey, V. Treyer, J. Streffer et al., “Human PET studies of metabotropic glutamate receptor subtype 5 with 11C-ABP688,” Journal of Nuclear Medicine, vol. 48, no. 2, pp. 247–252, 2007. View at Google Scholar · View at Scopus
  96. M. Kågedal, Z. Cselényi, S. Nyberg et al., “A positron emission tomography study in healthy volunteers to estimate mGluR5 receptor occupancy of AZD2066—estimating occupancy in the absence of a reference region,” NeuroImage, vol. 82, pp. 160–169, 2013. View at Publisher · View at Google Scholar · View at Scopus
  97. K. Kawamura, T. Yamasaki, K. Kumata et al., “Binding potential of (E)-[11C]ABP688 to metabotropic glutamate receptor subtype 5 is decreased by the inclusion of its 11C-labelled Z-isomer,” Nuclear Medicine and Biology, vol. 41, no. 1, pp. 17–23, 2014. View at Publisher · View at Google Scholar · View at Scopus
  98. F. G. Siméon, A. K. Brown, S. S. Zoghbi, V. M. Patterson, R. B. Innis, and V. W. Pike, “Synthesis and simple 18F-labeling of 3-fluoro-5-(2-(2- (fluoromethyl)thiazol-4-yl)ethynyl)benzonitrile as a high affinity radioligand for imaging monkey brain metabotropic glutamate subtype-5 receptors with positron emission tomography,” Journal of Medicinal Chemistry, vol. 50, no. 14, pp. 3256–3266, 2007. View at Publisher · View at Google Scholar · View at Scopus
  99. H. U. Shetty, S. S. Zoghbi, F. G. Simeon et al., “Radiodefluorination of 3-fluoro-5-(2-(2-[18F](fluoromethyl)-thiazol-4-yl)ethynyl)benzonitrile ([18F]SP203, a radioligand for imaging brain metabotropic glutamate subtype-5 receptors with positron emission tomography, occurs by glutathionylation in rat brain,” Journal of Pharmacology and Experimental Therapeutics, vol. 327, pp. 727–735, 2008. View at Google Scholar
  100. J. J. P. Bogaards, J. C. Venekamp, F. G. C. Salmon, and P. J. Van Bladeren, “Conjugation of isoprene monoepoxides with glutathione, catalyzed by α, μ, π and θ-class glutathione S-transferases of rat and man,” Chemico-Biological Interactions, vol. 117, no. 1, pp. 1–14, 1999. View at Publisher · View at Google Scholar · View at Scopus
  101. A. K. Brown, Y. Kimura, S. S. Zoghbi et al., “Metabotropic glutamate subtype 5 receptors are quantified in the human brain with a novel radioligand for PET,” Journal of Nuclear Medicine, vol. 49, no. 12, pp. 2042–2048, 2008. View at Publisher · View at Google Scholar · View at Scopus
  102. Y. Hao, R. Martin-Fardon, and F. Weiss, “Behavioral and functional evidence of metabotropic glutamate receptor 2/3 and metabotropic glutamate receptor 5 dysregulation in cocaine-escalated rats: factor in the transition to dependence,” Biological Psychiatry, vol. 68, no. 3, pp. 240–248, 2010. View at Publisher · View at Google Scholar · View at Scopus
  103. D. Martinez, M. Slifstein, N. Nabulsi et al., “Imaging glutamate homeostasis in cocaine addiction with the metabotropic glutamate receptor 5 positron emission tomography radiotracer [11C]ABP688 and magnetic resonance spectroscopy,” Biological Psychiatry, vol. 75, no. 2, pp. 165–171, 2014. View at Publisher · View at Google Scholar · View at Scopus
  104. M. S. Milella, L. Marengo, K. Larcher et al., “Limbic system mGluR5 availability in cocaine dependent subjects: a high-resolution PET [11C]ABP688 study,” Neuroimage, vol. 98, pp. 195–202, 2014. View at Google Scholar
  105. N. E. Paterson and A. Markou, “The metabotropic glutamate receptor 5 antagonist MPEP decreased break points for nicotine, cocaine and food in rats,” Psychopharmacology, vol. 179, no. 1, pp. 255–261, 2005. View at Publisher · View at Google Scholar · View at Scopus
  106. M. I. Palmatier, X. Liu, E. C. Donny, A. R. Caggiula, and A. F. Sved, “Metabotropic glutamate 5 receptor (mGluR5) antagonists decrease nicotine seeking, but do not affect the reinforcement enhancing effects of nicotine,” Neuropsychopharmacology, vol. 33, no. 9, pp. 2139–2147, 2008. View at Publisher · View at Google Scholar · View at Scopus
  107. F. Akkus, S. M. Ametamey, V. Treyer et al., “Marked global reduction in mGluR5 receptor binding in smokers and ex-smokers determined by [11C]ABP688 positron emission tomography,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 2, pp. 737–742, 2013. View at Publisher · View at Google Scholar · View at Scopus
  108. L. R. Merlin, “Differential roles for mGluR1 and mGluR5 in the persistent prolongation of epileptiform bursts,” Journal of Neurophysiology, vol. 87, no. 1, pp. 621–625, 2002. View at Google Scholar · View at Scopus
  109. T. Kirschstein, M. Bauer, L. Müller et al., “Loss of metabotropic glutamate receptor-dependent long-term depression via downregulation of mGluR5 after status epilepticus,” The Journal of Neuroscience, vol. 27, no. 29, pp. 7696–7704, 2007. View at Publisher · View at Google Scholar · View at Scopus
  110. H. Choi, Y. K. Kim, S. W. Oh et al., “In vivo imaging of mGluR5 changes during epileptogenesis using [11C]ABP688 PET in pilocarpine-induced epilepsy rat model,” PLoS ONE, vol. 9, no. 3, Article ID e92765, 2014. View at Publisher · View at Google Scholar · View at Scopus
  111. A. Deschwanden, B. Karolewicz, A. M. Feyissa et al., “Reduced metabotropic glutamate receptor 5 density in major depression determined by [11C]ABP688 PET and postmortem study,” The American Journal of Psychiatry, vol. 168, no. 7, pp. 727–734, 2011. View at Publisher · View at Google Scholar · View at Scopus
  112. M. J. Fell, D. L. McKinzie, J. A. Monn, and K. A. Svensson, “Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia,” Neuropharmacology, vol. 62, no. 3, pp. 1473–1483, 2012. View at Publisher · View at Google Scholar · View at Scopus
  113. M. Amalric, S. Lopez, C. Goudet et al., “Group III and subtype 4 metabotropic glutamate receptor agonists: discovery and pathophysiological applications in Parkinson's disease,” Neuropharmacology, vol. 66, pp. 53–64, 2013. View at Publisher · View at Google Scholar · View at Scopus
  114. N. K. Parelkar and J. Q. Wang, “Upregulation of metabotropic glutamate receptor 8 mRNA expression in the rat forebrain after repeated amphetamine administration,” Neuroscience Letters, vol. 433, no. 3, pp. 250–254, 2008. View at Publisher · View at Google Scholar · View at Scopus
  115. J. I. Andrés, J. Alcázar, J. M. Cid et al., “Synthesis, evaluation, and radiolabeling of new potent positive allosteric modulators of the metabotropic glutamate receptor 2 as potential tracers for positron emission tomography imaging,” Journal of Medicinal Chemistry, vol. 55, no. 20, pp. 8685–8699, 2012. View at Publisher · View at Google Scholar · View at Scopus
  116. K. V. Laere, M. Koole, J. Hoon et al., “Biodistribution, dosimetry and kinetic modeling of [11C]JNJ-42491293, a PET tracer for the mGluR2 receptor in the human brain,” Journal of Nuclear Medicine, vol. 53, supplement 1, article 355, 2012. View at Google Scholar
  117. D. W. Engers, C. M. Niswender, C. D. Weaver et al., “Synthesis and evaluation of a series of heterobiarylamides that are centrally penetrant metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulators (PAMs),” Journal of Medicinal Chemistry, vol. 52, no. 14, pp. 4115–4118, 2009. View at Publisher · View at Google Scholar · View at Scopus
  118. K.-E. Kil, Z. Zhang, K. Jokivarsi et al., “Radiosynthesis of N-(4-chloro-3-[11C]methoxyphenyl)-2- picolinamide ([11C]ML128) as a PET radiotracer for metabotropic glutamate receptor subtype 4 (mGlu4),” Bioorganic and Medicinal Chemistry, vol. 21, no. 19, pp. 5955–5962, 2013. View at Publisher · View at Google Scholar · View at Scopus
  119. M. Nakamura, H. Kurihara, G. Suzuki, M. Mitsuya, M. Ohkubo, and H. Ohta, “Isoxazolopyridone derivatives as allosteric metabotropic glutamate receptor 7 antagonists,” Bioorganic and Medicinal Chemistry Letters, vol. 20, no. 2, pp. 726–729, 2010. View at Publisher · View at Google Scholar · View at Scopus
  120. M. L. Vallano, B. Lambolez, E. Audinat, and J. Rossier, “Neuronal activity differentially regulates NMDA receptor subunit expression in cerebellar granule cells,” Journal of Neuroscience, vol. 16, no. 2, pp. 631–639, 1996. View at Google Scholar · View at Scopus
  121. K. W. Roche, S. Standley, J. McCallum, C. Dune Ly, M. D. Ehlers, and R. J. Wenthold, “Molecular determinants of NMDA receptor internalization,” Nature Neuroscience, vol. 4, no. 8, pp. 794–802, 2001. View at Publisher · View at Google Scholar · View at Scopus
  122. T. Hayashi, G. M. Thomas, and R. L. Huganir, “Dual palmitoylation of NR2 subunits regulates NMDA receptor trafficking,” Neuron, vol. 64, no. 2, pp. 213–226, 2009. View at Publisher · View at Google Scholar · View at Scopus